Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. has announced that its Board of Directors will hold a meeting on March 27, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. The meeting will also address the recommendation of a final dividend payment and other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and providing innovative medical solutions and therapies, with a particular emphasis on the Chinese market.
YTD Price Performance: 27.48%
Average Trading Volume: 9,707,354
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$5.71B
Learn more about 2157 stock on TipRanks’ Stock Analysis page.